Tumor necrosis factor polymorphisms in psoriatic arthritis association with the promoter polymorphism TNF-857 independent of the PSORS1 risk allele 英文参考文献.docVIP

下载本文档

1
0
约12.75万字
约 18页
2017-05-16 发布于上海
举报
版权申诉

Tumor necrosis factor polymorphisms in psoriatic arthritis association with the promoter polymorphism TNF-857 independent of the PSORS1 risk allele 英文参考文献.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Tumor necrosis factor polymorphisms in psoriatic arthritis association with the promoter polymorphism TNF-857 independent of the PSORS1 risk allele 英文参考文献

Available online /supplements/9/S3 Arthritis Research Therapy Volume 9 Suppl 3, 2007 6th Global Arthritis Research Network (GARN) Meeting Zurich, Switzerland 10-13 May 2007 Published online: 19 October 2007 These abstracts are available online at /supplements/9/S3 ? 2007 BioMed Central Ltd Arthritis models P2 Combined anti-inflammatory tritherapy using a novel small interfering RNA lipoplex successfully prevents and cures mice of arthritis P1 IL-21 modulates cytokine levels in murine collagen-induced arthritis and contributes to disease pathology M Khoury1,2, V Escriou3,4,5,6, A Galy7,8, R Yao7,8, C Largeau3,4,5,6, D Scherman3,4,5,6, C Jorgensen1,2,9, F Apparailly1,2 DA Young, M Hegen, H Ma, L Napierata, J Lamothe, M Senices, L Lowe, M Collins, C Nickerson-Nutter Inflammation, Wyeth Research, Cambridge, MA, USA Arthritis Research Therapy 2007, 9(Suppl 3):P1 (doi: 10.1186/ar2227) 1Inserm, U 844, INM, H?pital Saint Eloi, Montpellier, France; 2Université Montpellier1, UFR de Médecine, Montpellier, France; 3Inserm, U 640, Paris, France; 4CNRS, UMR8151, Paris, France; 5Université Paris Descartes, Faculté de Pharmacie, Paris, France; 6Ecole Nationale Supérieure de Chimie de Paris, Paris, France; 7Inserm, U 790, Genethon, Evry, France; 8Université Paris-Sud 11, Orsay, France; 9CHU Lapeyronie, service Immuno-Rhumatologie, Montpellier, France Arthritis Research Therapy 2007, 9(Suppl 3):P2 (doi: 10.1186/ar2228) Background IL-21 is secreted by activated T cells and modulates immune cell functions with both proinflammatory and anti-inflam- matory effects. IL-21 receptor (IL-21R), homologous to IL-2Rβ and IL-4Rα, associates with the gamma common chain upon ligand binding. It was recently described that IL-21R is overexpressed in the inflamed synovial membrane and on leucocytes of rheumatoid arthritis patients. Objective Previously we have shown that blockade of the IL-21 pathway with soluble IL-21R-Fc resulted in a reduction of clinical signs of